<DOC>
	<DOCNO>NCT02988297</DOCNO>
	<brief_summary>The purpose study determine whether nebulized RNS60 effective treatment amyotrophic lateral sclerosis ( ALS ) .</brief_summary>
	<brief_title>Nebulized RNS60 Treatment Amyotrophic Lateral Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<criteria>Probable , probablelaboratory support , definite ALS , either sporadic familial accord modify El Escorial criterion Disease duration &lt; 3 year Age 18 80 Able provide inform consent comply study procedure Subjects must take riluzole least 30 day , stable dose riluzole least 30 day , prior screening ( riluzolena√Øve participant permit study ) Women must lactate able become pregnant ( e.g . post menopausal , surgically sterile , use adequate birth control ) duration study , 3 month study completion Men practice contraception duration study 3 month completion Diagnosis motor neuron disease ALS ( e.g. , primary lateral sclerosis , progressive muscular atrophy , progressive bulbar palsy ) Clinically significant unstable medical condition ( ALS ) would pose risk participant participate study would impact survival functional disability next 12 month Abnormal liver function define aspartate aminotransferase ( AST ) and/or alanine aminotransferase ( ALT ) &gt; 3 time upper limit normal Renal insufficiency ( Glomerular Filtration Rate &lt; 60 ) Active pulmonary disease Prior poor compliance inhalation device The presence unstable psychiatric disease , cognitive impairment , dementia would impair ability participant provide inform consent , accord judgment principal investigator . History human immunodeficiency virus ( HIV ) infection , clinically significant chronic hepatitis , active infection . Active participation another ALS clinical trial within 30 day Screening Visit Other experimental treatment antiinflammatory/immunomodulatory medication use precede 3 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>